Patritumab deruxtecan clinical trials
Also written U3-1402 and MK-1022.
How each study uses patritumab deruxtecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the patritumab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 8
Merck Sharp & Dohme LLC (9) · Daiichi Sankyo (7) · SOLTI Breast Cancer Research Group (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · SCRI Development Innovations, LLC (1) · MedSIR (1) · Daiichi Sankyo Co., Ltd. (1) · Samsung Medical Center (1)
Often tested with
Tested in the same studies.
Sacituzumab tirumotecan (2) · Vibostolimab (1) · Boserolimab (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Rolistobart (1) · Ifinatamab deruxtecan (1) · Ramucirumab (1) · Paclitaxel (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test patritumab deruxtecan.
- Apr 2027Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerPhase 2 · Gustave Roussy, Cancer Campus, Grand Paris
- Apr 2027Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusionPhase 2 · Samsung Medical Center
- Sep 2027Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdPhase 1/2 · Gustave Roussy, Cancer Campus, Grand Paris
- Sep 2027A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 2 · Daiichi Sankyo
Studies
Open first, then newest update. How each study uses patritumab deruxtecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Written as Patritumab deruxtecan
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as Patritumab Deruxtecan
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Patritumab deruxtecan
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Patritumab deruxtecan
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT04165070Written as HER3-DXd
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 2Daiichi SankyoNCT06172478Written as HER3-DXd
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06731907Written as HER3-DXd
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06941272Written as Patritumab Deruxtecan
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Daiichi SankyoNCT07701941Written as Patritumab deruxtecan
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06298084Written as Patritumab deruxtecan
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06445972Written as HER3-DXd
- Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerRecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT04965766Written as U3-1402
- Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 FusionRecruitingPhase 2Samsung Medical CenterNCT06383884Written as Patritumab Deruxtecan
- HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingPhase 2Daiichi SankyoNCT04619004Written as Patritumab Deruxtecan (Fixed dose)
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruitingPhase 1Daiichi SankyoNCT03260491Written as HER3-DXd (FL-DP)
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingPhase 1Daiichi SankyoNCT04676477Written as HER3-DXd
- Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06596694Written as Patritumab deruxtecan
- HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyActive, not recruitingPhase 3Daiichi SankyoNCT05338970Written as Patritumab Deruxtecan
- A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerCompletedPhase 2SCRI Development Innovations, LLCNCT04699630Written as U3-1402
- HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal DiseaseCompletedPhase 2MedSIRNCT05865990Written as Patritumab deruxtecan
See all 25 studies that test patritumab deruxtecan →
Given beside what is tested · 1 — patritumab deruxtecan is usual care or a partner of the new treatment
Codes
What other systems call patritumab deruxtecan · ClinicalTrials.gg INT001428
- MeSH (NLM) C000710748patritumab deruxtecanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3XPI7EG4W8PATRITUMAB DERUXTECANConfirmed FDA, NLM
- NCI Thesaurus C136987Patritumab DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710748 | patritumab deruxtecan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3XPI7EG4W8 | PATRITUMAB DERUXTECAN | Confirmed FDA, NLM |
| NCI Thesaurus | C136987 | Patritumab Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.